Dr. Reddy’s Laboratories to acquire OctoPlus for €27.4m

Published: 22-Oct-2012
Drug Delivery Finance Pharmaceutical

Aims to build a research base in Leiden, The Netherlands


Indian pharmaceuticals manufacturer Dr Reddy’s Laboratories is to acquire Netherlands-based drug delivery technology firm OctoPlus for about €27.4m in cash in its aim to globalise its R&D.

Dr Reddy’s currently holds a commitment from shareholders representing more than 50% of OctoPlus’s issued and outstanding shares. The executive board and the supervisory board of OctoPlus have unanimously recommended the offer to the remaining shareholders.

‘As we globalise our R&D efforts, we are looking forward to build a research base in Leiden, The Netherlands. The acquisition helps us ramp up our technology capabilities in drug delivery,’ said G V Prasad, vice-chairman and CEO of Dr Reddy’s.

The transaction should be concluded by the end of the current fiscal year.

  • Companies:
  • OctoPlus
  • Dr Reddys Laboratories
See more

You may also like

Manufacturing

Aurigene expands CDMO facilities for viral vectors

Read more
The facility allows for maximum flexibility for a multi-product, multi-platform offering across therapeutic proteins, antibodies, and viral vectors

Trending Articles

  1. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  2. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  3. Pharmaceutics International bolsters its prefilled syringe production capabilities The aseptic and oral dosage CDMO has invested USD $3.6m into advanced labelling, fill/finish and automated visual inspection technologies at its Hunt Valley site in Maryland, US
  4. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  5. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Manufacturing

Aurigene expands CDMO facilities for viral vectors

The facility allows for maximum flexibility for a multi-product, multi-platform offering across therapeutic proteins, antibodies, and viral vectors
Manufacturing

Big names announced for leading Pharma and Cleanroom conference

The Cleanroom Technology Conference and Manufacturing Chemist Live collaboration will take place on the 10-11 November. Delegate tickets are currently available
Manufacturing

Dr. Reddy’s and TR-Pharm announce strategic collaboration in Turkey

Dr. Reddy’s and TR-Pharm have entered into a strategic collaboration agreement to manufacture and commercialise a portfolio of biosimilar drugs in Turkey
Pharmaceutical

Indian generic manufacturers aim to enter the Japanese market

The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Pharmaceutical

Dr. Reddy’s to distribute three Amgen medicines in India

In the areas of oncology and cardiology
Research & Development

Dr Reddy’s raises its R&D spending

Biosimilars account for around 15–20% of the overall R&D spend, representing US$45–60m
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Subscribe now